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Background: Older people represent the majority of cancer patients but their specific needs are often ignored in the
development of health-related quality of life (HRQOL) instruments. The European Organisation for Research and Treatment of
Cancer (EORTC) QLQ-ELD15 was developed to supplement the EORTC’s core questionnaire, the QLQ-C30, for measuring
HRQOL in patients aged 470 years in oncology studies.
Methods: Patients (n¼ 518) from 10 countries completed the QLQ-C30, QLQ-ELD15 and a debriefing interview. Eighty two
clinically stable patients repeated the questionnaires 1 week later (test–retest analysis) and 107 others, with an expected change in
clinical status, repeated the questionnaires 3 months later (response to change analysis, RCA).
Results: Information from the debriefing interview, factor analysis and item response theory analysis resulted in the removal of one
item (QLQ-ELD15-QLQ-ELD14) and revision of the proposed scale structure to five scales (mobility, worries about others, future
worries, maintaining purpose and illness burden) and two single items (joint stiffness and family support). Convergent validity was
good. In known-group comparisons, the QLQ-ELD14 differentiated between patients with different disease stage, treatment
intention, number of comorbidities, performance status and geriatric screening scores. Test–retest and RCA analyses were equivocal.
Conclusion: The QLQ-ELD14 is a validated HRQOL questionnaire for cancer patients aged X70 years. Changes in elderly
patients’ self-reported HRQOL may be related to both cancer evolution and non-clinical events.
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The European Organisation for Research and Treatment of Cancer
(EORTC) QLQ-C30 (Aaronson et al, 1993) is one of the most
widely used questionnaires for assessing health-related quality of
life (HRQOL) in cancer patients. However, the QLQ-C30 does not
meet all the needs of HRQOL assessment in cancer patients aged
470 years (Fitzsimmons et al, 2009; Johnson et al, 2010). There
are substantial age-related differences in response on the EORTC
QLQ-C30 (Hjermstad et al, 1998; Michelson et al, 2000; Schwarz
and Hinz, 2001). Older people with cancer have a different
HRQOL profile (Wright et al, 2005) and the specific needs of older
people are often ignored in the development, validation and use of
HRQOL instruments (Fitzsimmons et al, 2009). Similarly, healthy
individuals report age-related differences in factors affecting well-
being (Bowling, 2011). The QLQ-ELD15 was developed to
supplement the QLQ-C30, and to take into account age-specific
issues of relevance and importance to older cancer patients
(Johnson et al, 2010).
Although older people represent the majority of cancer patients,
there has been relatively little consideration for age-specific
HRQOL in this population (Lichtman et al, 2007) and, as far as
we know, no HRQOL instrument specifically designed for older
people with cancer (Fitzsimmons et al, 2009). This may be partly
explained by the under-representation of older patients in clinical
trials (Scher and Hurria, 2012). Special interest organisations are
now actively promoting research in elderly patients with cancer
(Lichtman, 2012; Wildiers et al, 2012), so appropriate patient-
reported outcome measures are required to assess HRQOL.
Health-related quality of life assessment is also important in
routine clinical practice (Greenhalgh, 2009). Elderly cancer patients
are more often treated with a non-curative approach and may be
vulnerable to treatment toxicities (Wedding et al, 2007). Measurement
of HRQOL aids the clinician in deciding whether the benefits of
treatment outweigh the associated side effects, provided the
instrument used is valid, reliable and responsive. We have
previously described the EORTC QLQ-ELD15, a questionnaire
designed to supplement the EORTC QLQ-C30, for use in older
patients with cancer (Johnson et al, 2010). The aim of the present
study was to test and, if necessary, modify the scale structure, along
with the reliability, responsiveness to change and validity of the
EORTC QLQ-ELD15 in conjunction with the EORTC QLQ-C30
in cancer patients aged X70 years.
METHODS
This prospective multi-centre cohort study followed the EORTC
Quality of Life Group guidelines for module development (Johnson
et al, 2011). The full protocol is available from the authors.
Patients. Patients were recruited from September 2010 to
December 2011 in four centres in the UK, three in France, two
in the Netherlands and one each in Australia, Austria, Cyprus,
Greece, Spain, Sweden and Taiwan. A convenience sample of
consecutive in-patients and outpatients who met the inclusion
criteria were invited to participate. Eligible patients had a
confirmed diagnosis of any primary, recurrent or metastatic
cancer, were aged 470 years at study entry and were capable of
providing written informed consent and completing HRQOL
questionnaires. Patients were excluded if they were participating in
other HRQOL investigations, or had a history of a different cancer
other than the primary cancer or previous localised skin cancer.
Three subgroups were considered: solid tumour, potentially
curative (Group A); solid tumour, palliative (Group B) and
haematological cancer (Group C).
Recruitment targets. The primary aim of the study was to
evaluate the hypothesised scale structure of the EORTC
QLQ-ELD15. The target sample size of 450 (225 patients each in
groups A and B) was determined by the number of items in the
questionnaire (15) and the accepted ‘rule of thumb’ that 15
responses per item are needed (Johnson et al, 2011). Additionally,
50 Group C participants were recruited for comparison with the
solid tumour patients.
Ethical and research governance approvals were obtained at
each centre in accordance with local requirements and all patients
provided written informed consent. The EORTC Quality of Life
Group approved the protocol. The study was coordinated from
Southampton and collaborators met every 6 months at EORTC
Quality of Life Study Group meetings.
Questionnaires and data collection. All patients completed the
EORTC QLQ-C30 (version 3.0) and QLQ-ELD15 at baseline. A
‘not applicable’ option was added at the request of the UK ethics
committee to the three items of the QLQ-ELD15 which mentioned
family (questions 35–37). In 29% of baseline questionnaires, the
‘not applicable’ option was omitted in error. A subset of patients,
who were predicted to be clinically stable, completed the
questionnaires again 1 week later (test–retest analysis) and a
different subset, predicted to have a different clinical status,
completed the questionnaires again 3 months after baseline
(response to change analysis, RCA).
EORTC translation guidelines (Koller et al, 2007) were used to
produce questionnaires in all the relevant languages. The
QLQ-ELD15 contains 15 items in five scales: mobility (Q31–34),
family support (Q35–36), worries about the future (Q37–41),
maintaining autonomy and purpose (Q42–Q43), and burden of illness
(Q44–45) (Johnson et al, 2010). All responses were converted to a
score of between 0 and 100 using a linear transformation following
EORTC guidelines (Fayers et al, 2001). High scores indicate poor
mobility, good family support, much worry about the future, good
maintenance of autonomy and purpose, and high burden of illness.
At baseline, participants completed a debriefing questionnaire
that recorded time for completion, whether any help was needed
and whether any of the items were upsetting, confusing or difficult
to answer. Additional comments were invited. Sociodemographic
and clinical data were recorded at each completion of the
questionnaires, along with the Charlson Comorbidity Index
(Charlson et al, 1987), Eastern Cooperative Oncology Group
(ECOG) Common Toxicity Criteria and Performance Status (Oken
et al, 1982), G-8 Geriatric Screening tool (Bellera et al, 2012)
and Instrumental Activities of Daily Living (IADL) (Lawton and
Brody, 1969).
Statistical analysis. Standard psychometric analyses were
employed to evaluate the QLQ-ELD15. All analyses were
performed using Stata/IC version 12 statistical software (Stata
Corporation, College Station, TX, USA).
Scaling. The construct validity of the QLQ-ELD15, that is whether
the individual items composing the questionnaire could be
aggregated into the five hypothesised scales described above, was
examined using multi-trait scaling. Construct validity comprises
convergent validity and discriminant validity. Convergent validity
is demonstrated when an item correlates highly with its own
hypothesised scale, defined as a correlation ofX0.40 (corrected for
overlap) (Fayers and Machin, 2007). Discriminant validity is
demonstrated when an item does not correlate highly with the
scales it is not part of. Discriminant validity was supported and
scaling success was identified when the correlation between an
item and its hypothesised scale (corrected for overlap) was 42
standard errors higher than its correlation with other scales.
Scaling failures were identified when an item correlated lower with
its hypothesised scale (corrected for overlap) than with other
scales.
Exploratory factor analysis (EFA), using principal factors and
oblique promax rotation, was used to explore the factor structure
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of the QLQ-ELD15 (Fayers and Machin, 2007). The first model
tested was based on the hypothesised five-scale structure described
above. Item response theory (IRT) analyses were also used to check
the proposed scale structure (Fayers and Machin, 2007).
Reliability. Two types of reliability were assessed: internal
reliability is tested by examining the homogeneity of the multi-
items scales and test–retest reliability is tested by checking whether
the same responses are given when the instrument is completed on
two separate occasions, a short time apart. The internal reliability
of the QLQ-ELD15 was explored using Cronbach’s a coefficient,
with a value of X0.70 regarded as adequate (Fayers and Machin,
2007). The test–retest reliability of scales was examined using
intraclass correlations (ICC) on the scores from assessment 1 and 2
with an ICC of X0.70 regarded as adequate.
Convergent validity. To assess scale-convergent validity, correla-
tions between conceptually related scales on the QLQ-ELD15 and
QLQ-C30 were examined using Pearson’s product moment
correlation. It was expected that those scales that are conceptually
related would correlate substantially with one another (Pearson’s
r40.40). These scales were mobility (QLQ-ELD15) vs physical
functioning (QLQ-C30), worries about the future (QLQ-ELD15) vs
emotional functioning (QLQ-C30), maintaining autonomy and
purpose (QLQ-ELD15) vs role functioning (QLQ-C30), and
burden of illness (QLQ-ELD15) vs global health/QOL (QLQ-C30).
Known-group comparisons. The extent to which the QLQ-ELD15
differentiates between groups of patients was assessed using the
method of known-group comparisons (Fayers and Machin, 2007).
The worries about the future scale was predicted to differentiate
subgroups based on treatment intention and disease stage.
Subgroups based on Charlson comorbidity, ECOG and G-8 score,
were predicted to be differentiated by mobility, worries about the
future, maintaining autonomy and purpose, and burden of illness
scales.
Responsiveness to change analysis. We used t-tests to test for the
significance of changes in scores at the two assessment times. We
expected changes on all the scales.
RESULTS
Of 518 patients recruited, 275 were in Group A, 170 were in Group
B and 54 were in Group C. Nineteen patients with solid tumours
without information on treatment intention were assigned to an
additional Group D. Further, 176 patients were from Northern
Europe, 147 from Western Europe, 116 from Southern Europe and
79 from the rest of the world. Patient sociodemographic and
clinical details are summarised in Table 1. The time taken to
complete the QLQ-ELD15 was recorded for 416 participants; 391
tookp15min. Help to complete the questionnaire was required by
209 patients, predominantly reading and/or writing. Forty five
patients reported finding at least one of the questions confusing or
difficult to answer and 22 found at least one question upsetting but
no question was found difficult or upsetting by more than 6
patients. A few patients provided additional comments: five
patients queried why all the questions referred to the last week,
two patients suggested that their answers were predominantly
determined by their age and other illnesses, and one patient
commented on how his responses were context-dependent.
The responses of Groups A and B combined together to the
QLQ-ELD15 were compared graphically with those of Group C
(data not shown). The distributions of responses were very similar.
In addition, differential item functioning confirmed that there were
no significant differences in the response probabilities across all
items for the two groups (probability range: 0.21–1.00). This
suggests that there is no difference in the responses given by
patients with solid and haematological cancers who have the same
HRQOL. The decision was therefore made that no additional
haematological patients were required, and that it was reasonable
to combine the data from solid and haematological malignancies.
Item and scale structure review. The authors reviewed the
content of any item identified as confusing or upsetting. Item 35,
‘Has your relationship with your family became closer?’, was
removed because the wording was problematic (patients who were
already close to their family found this difficult to answer) and the
time frame was inappropriate (unlikely to be applicable for most
people in the last week). This left just one item, item 36, ‘Have you
felt able to talk to your family about your illness?’, in the family
support scale. This item was retained as a single item because it is
important and relevant to elderly patients. An EFA (not shown)
suggested that the hypothesised future worries scale should be split
into two, with items 37 and 38 forming one scale (worries about
others) and items 39–41 forming another scale (future worries).
The EFA also indicated that item 32, ‘Have you had trouble with
your joints (e.g. stiffness and pain)?’, contributed little to the
mobility scale. Item response theory analyses (not shown) also
supported removing item 32 from the mobility scale as it showed
poor fit with the other items and contributed little additional
information to the scale. The authors decided to retain item 32 as a
single item because of its clinical relevance. Table 2 shows the items
and revised scale structure of the EORTC QLQ-ELD14 (note the
change from QLQ-ELD15). The QLQ-ELD14 comprises 14 items,
made up of 5 scales and 2 single items. Item response theory
analyses of the revised scales did not reveal any poorly performing
items, and inspection of the contribution of each item to the
respective scale total-information plots supported the proposed
scale structure and the retention of items. The results reported
below are all based on the QLQ-ELD14.
Scaling. Results from the multi-trait scaling analyses are shown in
Table 3. There were no scaling failures. The EFA supported the
proposed scale structure but the single item joint stiffness
correlated with the three-item mobility scale (r¼ 0.48). Exploratory
factor analysis therefore suggested a single composite score that
combined all four items. However, joint stiffness is conceptually
different from the other mobility scale items and as the correlation was
modest, we decided to retain joint stiffness as a separate single item.
Reliability. Table 3 indicates that all the scales met the criterion
for internal consistency except the maintaining purpose scale,
which fell just short of our chosen threshold for adequate internal
consistency (0.68 vs 0.70). For the test–retest analysis, ICCs were
adequate for four scales and one single item. The low ICCs for
burden of illness and family support were reflected by a statistically
significant reduction in burden (P¼ 0.003) and increase in family
support (P¼ 0.009). Because of the unexpected differences, a
similar test–retest analysis was carried out for the QLQ-C30; this
showed a significant worsening of physical (P¼ 0.020), role
(P¼ 0.015) and social functioning (P¼ 0.014).
Convergent validity. Correlations between the QLQ-C30 and
QLQ-ELD14 are shown in Table 4. Three of four scale pairs
predicted to be conceptually related did correlate substantially with
one another (r40.4), but the maintaining purpose (QLQ-ELD14)
and role functioning (QLQ-C30) scales did not correlate well
(r¼ 0.18). Other correlations with r40.4 that had not been
predicted a priori were mobility (QLQ-ELD14) with social and role
functioning, and with global health/QOL; burden of illness
(QLQ-ELD14) with the physical, social and role functioning scales;
the single item joint stiffness with physical functioning, and the
future worries scale with social functioning.
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Known-group comparisons. Table 5 shows the significant
P-values in the known-group comparisons analyses. For the
disease stage and treatment intention analyses, the only differences
were on the future worries scale. Mobility, joint stiffness and
maintaining purpose discriminated between patients with differing
numbers of comorbidities. Patients above and below the cutoff
(a score of 14) on the G-8 scored differently on each of the five
multi-item scales, but not the two single items, and all seven scales
differentiated patients with different ECOG scores.
Responsiveness to change analysis. Although patients likely to
show a change in clinical status were selected for the RCA, many of
those included remained stable. We therefore used the ECOG to
define groups for the RCA. We predicted that patients who
improved on the ECOG would also improve on the mobility scale,
and that patients whose performance status declined would have
higher scores (worse mobility). Patients with worse ECOG (n¼ 13)
had significantly worse scores on the mobility scale (P¼ 0.038).
There was no improvement on the mobility scale in 19 patients
with improved ECOG (P¼ 0.58).
DISCUSSION
This study examined the reliability, validity and psychometric
properties of the EORTC QLQ-ELD15 in an international sample
of 518 elderly patients, across 10 countries and in 8 languages. One
item was removed from the module, due to problems with wording
and content. The revised QLQ-ELD14 comprises five scales
(mobility, worries about others, future worries, maintaining
purpose and burden of illness) and two single items (joint stiffness
Table 1. Patient sociodemographic and clinical details
Group A (n¼275) Group B (n¼170) Group C (n¼54) Group D (n¼19) Total (n¼518)
Mean, s.d. (age, years) 76.9 (4.6) 77.9 (5.1) 76.9 (5.2) 79.2 (6.3) 77.3 (4.9)
Median, range (age, years) 76 (70–94) 77 (70–95) 76 (70–96) 79 (71–91) 77 (70–96)
Gender, male 138 (50.2) 80 (47.1) 27 (50.9)
n¼ 53
8 (42.1) 253 (48.8)
n¼ 517
Currently married/with partner 178 (64.7) 104 (61.5)
n¼ 169
33 (61.1) 10 (52.6) 325 (62.9)
n¼ 517
Living alone 71 (25.8) 40 (23.5) 12 (22.2) 8 (42.1) 131 (25.3)
Carer easily available 219 (82.0)
n¼ 267
145 (86.3)
n¼ 168
29 (78.4)
n¼ 37
16 (88.9)
n¼ 18
409 (83.5)
n¼ 490
Education beyond secondary school 70 (25.7)
n¼272
42 (25.1)
n¼ 167
19 (36.5)
n¼ 52
7 (38.9)
n¼ 18
138 (27.1)
n¼ 509
Previous professional level employment 45 (16.5)
n¼ 273
26 (15.5)
n¼ 168
10 (27.8)
n¼ 36
4 (22.2)
n¼18
85 (17.2)
n¼ 495
Mean G-8 score (s.d.) 12.8 (2.8) 12.1 (3) 12.4 (3.4) 11.8 (2.9) 12.5 (2.9)
Mean IADL score (s.d.) 6.3 (1.9) 5.8 (2.2) 5.9 (2.1) 6.7 (1.9) 6.1 (2)
Has 1þ Charlson comorbidities 116 (42.2) 59 (34.7) 13 (24.1) 9 (47.4) 197 (38.0)
ECOG score
(n¼265) (n¼168) (n¼34) (n¼12) (n¼479)
0 117 (44.2) 55 (32.7) 13 (38.2) 2 (16.7) 187 (39.0)
1 92 (34.7) 63 (37.5) 10 (29.4) 7 (58.3) 172 (35.9)
2 33 (12.5) 32 (19.0) 9 (26.5) 1 (8.3) 75 (15.7)
3 20 (7.5) 15 (8.9) 1 (2.9) 2 (16.7) 38 (7.9)
4 3 (1.1) 3 (1.8) 1 (2.9) 0 (0) 7 (1.5)
Toxicity level
None 200 (72.7) 86 (50.6) 37 (68.5) 17 (89.5) 340 (65.6)
Mild 63 (22.9) 68 (40.0) 11 (20.4) 2 (10.5) 144 (27.8)
Severe 12 (4.4) 16 (9.4) 6 (11.1) 0 (0) 34 (6.6)
Primary tumour
Breast 59 (21.5) 26 (15.3) 0 (0) 6 (31.6) 91 (17.6)
Colorectal 51 (18.5) 33 (19.4) 0 (0) 3 (15.8) 87 (16.8)
Lung 38 (13.8) 25 (14.7) 0 (0) 0 (0) 63 (12.2)
Ovary 10 (3.6) 13 (7.6) 0 (0) 0 (0) 23 (4.4)
Prostate 48 (17.5) 23 (13.5) 0 (0) 4 (21.1) 75 (14.5)
Upper GI 10 (3.6) 10 (5.9) 0 (0) 1 (5.3) 21 (4.1)
Other 59 (21.5) 40 (23.5) 0 (0) 5 (26.3) 104 (20.1)
Haematological 0 (0) 0 (0) 54 (100) 0 (0) 54 (10.4)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; GI¼ ; gastrointestinal; IADL¼ instrumental activities of daily living scale; s.d.¼ standard deviation. Group A: solid tumour,
curative; group B: solid tumour, palliative; group C haematological; group D other. Values in parentheses are percentages unless indicated otherwise.
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and family support). The questionnaire is appropriate for patients
with all types of malignancy and provides a patient-reported
measure of HRQOL in line with the views expressed by patients
during the development process (Johnson et al, 2010). Unlike
EORTC site-specific modules, the QLQ-ELD14 has a strong focus
on psychosocial issues. It is able to discriminate between groups of
patients defined by disease stage, number of comorbidities,
treatment intention, performance status and normal or abnormal
G-8 score.
Almost all patients completed the questionnaire in less than
15 min, although many needed help with reading the questions and
filling out the answers, usually because reading glasses were not
available. No major omissions were identified in the debriefing
interviews ando1.5% of patients described any item as difficult to
understand or upsetting. We conclude that the QLQ-ELD14 is
acceptable, quick and easy to complete, and has good content
validity. Convergent validity was established by significant
correlations between mobility and physical functioning, worries
about the future and emotional functioning, and burden of illness
and global health/QOL. Maintaining purpose and role functioning
had also been predicted to correlate significantly with each other
but only a modest correlation was observed. This may be explained
by different emphasis of the scales: although both scales ask about
hobbies and usual activities, the maintaining purpose scale covers
motivation and ‘positive outlook’ while the role functioning scale
asks about limitations in ability to work and perform daily
activities.
Along with the predicted substantial correlations there were a
number of relationships that had not been anticipated. However,
all these associations were plausible. For example, mobility
correlated with social and role functioning, both of which are
concerned with whether physical condition had an impact on
everyday life (either family/social life or work/hobbies). It seems
reasonable that mobility can have an effect on these activities.
Mobility also correlated with the global health and QOL score.
These observations emphasise the central importance of mobility
to HRQOL in elderly cancer patients. Joint stiffness was retained as
a separate item because psychometric analyses indicated that it
should not be part of the mobility scale but it had been strongly
supported by patients as an important issue in the Phase 1
qualitative interviews (Johnson et al, 2010).
Previous development work (Johnson et al, 2010) had not
tested the QLQ-ELD14 in patients with haematological cancers.
Differential item functioning and comparison of the response
pattern found no evidence of any differences between the two
groups suggesting that the QLQ-ELD14 is appropriate for patients
with haematological malignancies.
Although the reliability analysis showed that the maintaining
purpose scale fell just short of the threshold for adequate internal
consistency, this scale has good face validity. The weaker internal
consistency suggests differences between the two concepts in this
scale (positive outlook and motivation for activities), but it was
agreed to retain the scale in its original form.
The test–retest reliability of the instrument was generally good.
Unexpectedly, there was a significant improvement in the family
support item and a significant reduction in illness burden. All the
patients appeared clinically stable, although it was not possible to
corroborate this with objective measures. There were also some
unexpected changes on the QLQ-C30 between the two time points,
with physical, role and social functioning all getting significantly
Table 2. EORTC QLQ-ELD14
Scale Item
Mobility 31. Have you had difficulty with steps or stairs?
Single item: joint stiffness 32. Have you had trouble with your joints (e.g. stiffness and pain)?
Mobility 33. Did you feel unsteady on your feet?
Mobility 34. Did you need help with household chores such as cleaning or shopping?
Single item: family support 35. Have you felt able to talk to your family about your illness?
Worries about others 36. Have you worried about your family coping with your illness and treatment?
Worries about others 37. Have you worried about the future of people who are important to you?
Future worries 38. Were you worried about your future health?
Future worries 39. Did you feel uncertain about the future?
Future worries 40. Have you worried about what might happen towards the end of your life?
Maintaining purpose 41. Have you had a positive outlook on life in the last week?
Maintaining purpose 42. Have you felt motivated to continue with your normal hobbies and activities?
Burden of illness 43. How much has your illness been a burden to you?
Burden of illness 44. How much has your treatment been a burden to you?
Table 3. Multi-trait scaling analyses and reliability of the scales in the
QLQ-ELD14a
Scale
(number of
items)
Item
correlation
within scaleb
Item correlation
with other scales
Cronbach’s
a
Mobility (3) 0.60–0.61 0.02–0.50 0.78
Joint stiffness
(1)
— 0.02–0.48 —
Family
support (1)
— 0.02–0.35 —
Worries about
others (2)
0.56 0.02–0.40 0.72
Future worries
(3)
0.67–0.80 0.04–0.45 0.86
Maintaining
purpose (2)
0.52 0.00–0.32 0.68
Burden of
illness (2)
0.68 0.02–0.49 0.81
an¼ 481.
bCorrected for overlap.
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worse. It is possible that these changes in response to the QLQ-C30
and the QLQ-ELD14 were influenced by non-clinical factors such
as interaction with family, which may have changed subjective
feelings of dependency and functional ability. For example, more
family support during the last week may have reduced the patient’s
perception of disease burden and need for physical activity.
Responsiveness to change was difficult to assess because many
patients selected for RCA did not show a change in their clinical
status. We therefore defined groups with an objective measure of
change (ECOG worse or better). Patients with a lower function
scored worse on the mobility scale on the second administration.
There was no improvement in the scale score for patients with
improved ECOG category. As in the test–retest analysis, context
may have influenced the RCA. In retrospect, it would have been
better to select patients for the RCA using documented evidence of
change, rather than a prediction. Although the RCA was equivocal,
we feel that this relative weakness is outweighed by the strengths of
the QLQ-ELD14: content, convergent and face validity are all good.
Given that everyday life events have an impact on QOL over a
short period in a general sample of elderly participants (Bowling,
2009), it is likely everyday life events will also have a significant
role in the HRQOL of elderly cancer patients, and so should be
assessed alongside HRQOL.
Potential applications of the QLQ-ELD14 complement physi-
cian-rated data and the existing QLQ-C30 and site-specific
modules of the EORTC HRQOL questionnaires. The QLQ-C30
is a generic cancer questionnaire; the site-specific modules explore
HRQOL issues related to specific tumour types in depth. The
QLQ-ELD14 addresses generic issues affecting older people with
cancer, not covered by the QLQ-C30 or site-specific modules, and
can be used in clinical studies that include older patients, regardless
of tumour site. Perhaps it’s greatest use will be in the evaluation of
the effect of changes in cancer services across a range of tumour
sites.
CONCLUSION
The EORTC QLQ-ELD14 in conjunction with the QLQ-C30 is the
first age-specific instrument for assessing HRQOL in cancer
patients and is suitable, acceptable and validated for patients aged
470 years. Factors other than clinical status may affect elderly
Table 5. Means, F-statistics and probability values for significant results on the known-groups analysis
Scale
Curative
(n¼288) vs
palliative
(n¼189)
One (n¼118) vs two
(n¼41) vs
threeþ (n¼38) Charlson
comorbidities
Local (n¼190) vs local
advanced (n¼99) vs
metastatic (n¼168)
ECOG score zero (n¼187)
vs one (n¼172) vs two
(n¼75) vs three/four
(n¼45)
Above cutoffa on G-8
(n¼212) vs below cut
off on G-8 (n¼287)
Mobility — 31.8 vs 49.5 vs 47.4, F¼ 7.20,
P¼0.001
— 10.9 vs 31.4 vs 44.4 vs 72.5,
F¼109.37, Po0.001
40.7 vs 20.6, F¼66.18,
Po0.001
Joint
stiffness
— 32.5 vs 43.9 vs 49.1, F¼ 4.09,
P¼0.018
— 19.8 vs 30.6 vs 40.0 vs 48.9,
F¼14.92, Po0.001
—
Family
support
— — — 76.5 vs 67.3 vs 66.2 vs 77.8,
F¼ 3.08, P¼ 0.027
—
Worries
about
others
— — — 34.0 vs 40.0 vs 44.9 vs 45.2,
F¼ 2.84, P¼ 0.037
44.8 vs 35.3, F¼10.25,
P¼0.001
Future
worries
31.3 vs 38.5,
F¼5.79,
P¼0.017
— 31.1 vs 31.2 vs 42.4,
F¼ 6.61, P¼0.001
25.1 vs 34.9 vs 48.1 vs 45.7,
F¼12.21, Po0.001
40.6 vs 29.8, F¼14.27,
Po0.001
Maintaining
purpose
— 67.1 vs 55.0 vs 57.5, F¼ 3.42,
P¼0.035
— 71.6 vs 63.5 vs 55.8 vs 56.8,
F¼6.84, Po0.001
58.7 vs 69.6, F¼16.60,
Po0.001
Burden of
illness
— — — 28.5 vs 43.8 vs 57.8 vs 66.3,
F¼28.27, Po0.001
54.0 vs 32.9, F¼55.55,
Po0.001
Abbreviation: ECOG¼Eastern Cooperative Oncology Group. Results not shown P40.05.
aCutoff is 14.
Table 4. Pearson’s product moment correlations between QLQ-ELD14 and QLQ-C30 scalesa
Mobility
Joint
stiffness
Family
support
Worries about
others
Future
worries
Burden of
illness
Maintaining
purpose
Physical functioning 0.79b  0.42b 0.06 0.14 0.30  0.47b 0.17
Social functioning 0.41b  0.22 0.09 0.26 0.49b  0.57b 0.19
Emotional functioning 0.37  0.26 0.09 0.19 0.41b  0.37 0.20
Role functioning 0.57b  0.25 0.04 0.18 0.35  0.52b 0.18
Global health status/
QoL
0.54b  0.35 0.06 0.18 0.36  0.48b 0.21
Abbreviation: QoL¼quality of life.
an¼ 475.
br40.4.
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patients more than younger patients and future studies should
explore this hypothesis.
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